Nonsurgical permanent contraception for women: Let's complete the job

Jeffrey T. Jensen

doi:10.1016/j.contraception.2015.06.010

Nonsurgical permanent contraception for women: Let's complete the job

Jeffrey T. Jensen

Obstetrics and Gynecology

Research output: Contribution to journal › Editorial › peer-review

2 Scopus citations

Original language	English (US)
Pages (from-to)	89-90
Number of pages	2
Journal	Contraception
Volume	92
Issue number	2
DOIs	https://doi.org/10.1016/j.contraception.2015.06.010
State	Published - Aug 1 2015

ASJC Scopus subject areas

Reproductive Medicine
Obstetrics and Gynecology

Access to Document

10.1016/j.contraception.2015.06.010

Cite this

@article{78889985640142e1b9de90236fbf5939,

title = "Nonsurgical permanent contraception for women: Let's complete the job",

author = "Jensen, {Jeffrey T.}",

note = "Funding Information: Financial Disclosure: Dr. Jensen has received payments for consulting from Agile Pharmaceuticals, Abbvie Pharmaceuticals, Bayer Healthcare, ContraMed, Evofem, HRA Pharma, Merck Pharmaceuticals, Teva Pharmaceuticals and the Population Council, and for giving talks for Bayer and Merck. He has also received research funding from Abbvie, Bayer, the Population Council, the National Institute of Health and the Bill & Melinda Gates Foundation. These companies and organizations may have a commercial or financial interest in the results of this research and technology. These potential conflicts of interest have been reviewed and managed by OHSU. ",

year = "2015",

month = aug,

day = "1",

doi = "10.1016/j.contraception.2015.06.010",

language = "English (US)",

volume = "92",

pages = "89--90",

journal = "Contraception",

issn = "0010-7824",

publisher = "Elsevier USA",

number = "2",

}

TY - JOUR

T1 - Nonsurgical permanent contraception for women

T2 - Let's complete the job

AU - Jensen, Jeffrey T.

N1 - Funding Information: Financial Disclosure: Dr. Jensen has received payments for consulting from Agile Pharmaceuticals, Abbvie Pharmaceuticals, Bayer Healthcare, ContraMed, Evofem, HRA Pharma, Merck Pharmaceuticals, Teva Pharmaceuticals and the Population Council, and for giving talks for Bayer and Merck. He has also received research funding from Abbvie, Bayer, the Population Council, the National Institute of Health and the Bill & Melinda Gates Foundation. These companies and organizations may have a commercial or financial interest in the results of this research and technology. These potential conflicts of interest have been reviewed and managed by OHSU.

PY - 2015/8/1

Y1 - 2015/8/1

UR - http://www.scopus.com/inward/record.url?scp=84937428706&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84937428706&partnerID=8YFLogxK

U2 - 10.1016/j.contraception.2015.06.010

DO - 10.1016/j.contraception.2015.06.010

M3 - Editorial

C2 - 26116034

AN - SCOPUS:84937428706

SN - 0010-7824

VL - 92

SP - 89

EP - 90

JO - Contraception

JF - Contraception

IS - 2

ER -

Nonsurgical permanent contraception for women: Let's complete the job

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this